M
Marieke Pierik
Researcher at Maastricht University Medical Centre
Publications - 156
Citations - 5619
Marieke Pierik is an academic researcher from Maastricht University Medical Centre. The author has contributed to research in topics: Inflammatory bowel disease & Medicine. The author has an hindex of 36, co-authored 115 publications receiving 4195 citations. Previous affiliations of Marieke Pierik include Katholieke Universiteit Leuven & Maastricht University.
Papers
More filters
Journal ArticleDOI
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
Mirthe E. van der Valk,Marie-Josée J. Mangen,Max Leenders,Gerard Dijkstra,Ad A. van Bodegraven,Herma H. Fidder,Dirk J. de Jong,Marieke Pierik,C. Janneke van der Woude,Mariëlle Romberg-Camps,Cees H. M. Clemens,Jeroen M. Jansen,Nofel Mahmmod,Paul C. van de Meeberg,Andrea E. van der Meulen-de Jong,Cyriel Y. Ponsioen,Clemens J. M. Bolwerk,J. Reinoud Vermeijden,Peter D. Siersema,Martijn G.H. van Oijen,Martijn G.H. van Oijen,Bas Oldenburg,Colitis +22 more
TL;DR: Assessment of healthcare costs and productivity losses in a large cohort of IBD patients showed that healthcare costs are mainly driven by medication costs, most importantly by anti-TNFα therapy.
Journal ArticleDOI
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
TL;DR: This data indicates that once the once-weekly infusions used in head-to-head trials for ulcerative colitis patients were discontinued, the use of these therapies in patients with inflammatory bowel disease should be considered to be safe and effective.
Journal ArticleDOI
Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients
TL;DR: Further well designed studies based on intention-to-treat analyses by several independent research groups are still warranted to support the promising results for E. coli Nissle in inactive UC and the multispecies product VSL#3 in active UC and inactive pouch patients.
Journal ArticleDOI
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease
Geert R. D'Haens,Severine Vermeire,Guy Lambrecht,Filip Baert,Peter Bossuyt,Benjamin Pariente,Anthony Buisson,Yoram Bouhnik,Jérôme Filippi,Janneke van der Woude,Philippe Van Hootegem,Jacques Moreau,Edouard Louis,Denis Franchimont,Martine De Vos,Fazia Mana,Laurent Peyrin-Biroulet,Hedia Brixi,Matthieu Allez,Philip Caenepeel,Alexandre Aubourg,Bas Oldenburg,Marieke Pierik,Ann Gils,Sylvie Chevret,David Laharie,Patricia Détré,Marie Jo Bertin,Sabrina Williams +28 more
TL;DR: In a prospective randomized exploratory trial of patients with active CD, increasing dose of infliximab based on a combination of symptoms, biomarkers, and serum drug concentrations does not lead to corticosteroid-free clinical remission in a larger proportion of patients than increasing dose based on symptoms alone.
Journal ArticleDOI
Fatigue and health-related quality of life in inflammatory bowel disease: Results from a population-based study in the Netherlands: The IBD-South Limburg cohort.
Mariëlle Romberg-Camps,Y Bol,Pieter C. Dagnelie,M A M Hesselink-van de Kruijs,Arnold D. M. Kester,Leopold G.J.B. Engels,C. van Deursen,Wim Hameeteman,Marieke Pierik,Frank Wolters,Maurice G. Russel,Reinhold W. Stockbrügger +11 more
TL;DR: Investigation in patients included in a population‐based IBD cohort in the Netherlands found that in IBD patients physicians need to be aware of fatigue in order to better understand its impact and to improve the HRQoL.